Wound Healing
Peptides for wound healing — GHK-Cu (the best-evidenced), BPC-157, TB-500, LL-37, and AC-SDKP. What the wound-care literature actually shows.
Wound healing is one of the few areas where peptide therapeutics have moved from theoretical to clinically supported. Skin and soft-tissue repair runs through a well-defined four-stage cascade — hemostasis, inflammation, proliferation, remodeling — and peptides have been characterized at virtually every step of that cascade. GHK-Cu has the longest and richest evidence base, with five decades of research from Loren Pickart and François-Xavier Maquart's group plus a 100-patient randomized controlled trial in post-laser-resurfacing wound healing. BPC-157 and TB-500 contribute strong preclinical wound-healing data of their own, and LL-37 (the human cathelicidin antimicrobial peptide) plays a dual role as both pathogen defense and re-epithelialization signal in diabetic ulcers and chronic wounds.
This page covers peptides discussed for wound healing across the spectrum: routine surgical and laser-resurfacing recovery, traumatic skin injuries, diabetic foot ulcers, chronic venous wounds, and post-procedure dermatology. The evidence quality varies dramatically by indication — strong for cosmetic-procedure recovery, plausible for chronic ulcers, anecdotal for most surgical applications.
For reference, the conventional wound-healing toolkit (negative-pressure wound therapy, hyperbaric oxygen, growth-factor preparations like becaplermin gel, advanced dressings, surgical debridement) remains the foundation of clinical wound care. Peptides sit as adjuncts and cosmetic applications, not as replacements for established interventions.
Peptides discussed for Wound Healing
GHK-Cu
Copper Peptide
The most-studied copper peptide in skincare — a naturally occurring tripeptide (GHK, Gly-His-Lys) whose active tissue form is the copper complex GHK-Cu, with extensive evidence for skin remodeling, collagen synthesis, wound healing, and anti-aging.
BPC-157
Gastric Peptide
A synthetic peptide derived from a protective protein found in gastric juice, widely discussed for tissue repair and recovery.
TB-500
Tissue Repair Peptide
A synthetic version of the active region of thymosin beta-4, widely used for tissue repair, wound healing, and recovery from injuries.
Ac-SDKP
Endogenous Antifibrotic Peptide
An endogenous tetrapeptide cleaved from thymosin β4 with broad antifibrotic activity across the heart, kidney, lung, and liver — historically developed as the chemoprotective drug goralatide and more recently studied as a biomarker of ACE-inhibitor activity.
LL-37
Antimicrobial Peptide
A naturally occurring antimicrobial peptide that plays a key role in innate immune defense.
How peptides target wound healing
Five mechanisms make peptides relevant to wound healing. First, GHK-Cu acts as a copper-delivery and signaling molecule. The peptide forms a stable square-planar complex with copper(II) and at the wound site delivers copper to lysyl oxidase (which crosslinks collagen and elastin) while simultaneously upregulating expression of collagen synthesis genes, decorin, antioxidant enzymes, and metalloproteinases that remodel the extracellular matrix. The 2010 Broad Institute Connectivity Map analysis underlying Pickart's 2014 BioMed Research International review documented coordinated expression changes across roughly 4,000 human genes.
Second, BPC-157 promotes angiogenesis and granulation tissue formation. Animal models of cutaneous wounds show faster wound closure, increased capillary density, and improved tensile strength of healed skin. The mechanism involves nitric oxide system modulation and growth factor receptor upregulation (VEGF, FGF, EGR-1) at the wound margin.
Third, TB-500 (thymosin beta-4 active region) drives actin polymerization and cell migration into the wound bed. Synthetic thymosin beta-4 has been studied clinically for corneal wounds, dermal pressure ulcers, and venous stasis ulcers (RegeneRx Biopharmaceuticals' RGN-137 program reached Phase II for various wound indications, with mixed results that did not produce a marketed product but did establish a credible signal).
Fourth, LL-37 (the human cathelicidin antimicrobial peptide) does double duty. It clears bacteria from the wound surface and signals re-epithelialization, fibroblast migration, and angiogenesis through formyl peptide receptor (FPR-2) signaling. LL-37 deficiency at wound sites has been characterized in chronic non-healing diabetic ulcers, and exogenous LL-37 has been studied as a topical wound-healing therapeutic.
Fifth, AC-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline, a tetrapeptide) has documented anti-fibrotic and anti-inflammatory effects relevant to scar quality and remodeling-phase wound healing.
What the evidence shows
GHK-Cu has the strongest human evidence in this peptide class. The 2007 Abdulghani et al. randomized controlled trial in 100 patients undergoing CO₂ laser resurfacing of the face showed reduced erythema and faster recovery with topical GHK-Cu post-procedure, and multiple smaller human studies have supported its role as a wound-recovery adjunct. The animal data are extensive — Maquart's 1988 FEBS Letters paper on fibroblast collagen synthesis, the 1993 Journal of Clinical Investigation paper on connective tissue accumulation in rat experimental wounds, the 2000 Siméon Journal of Investigative Dermatology paper on wound proteoglycans — all reinforce the same biological story.
BPC-157 and TB-500 have credible preclinical wound-healing data but no large randomized controlled trial in humans for cutaneous wound indications. Synthetic thymosin beta-4 reached Phase II clinical trials in pressure ulcers, venous stasis ulcers, and epidermolysis bullosa with signals of efficacy but did not advance to approval. The wound-healing field's view of these peptides is generally that the biology is real, the animal effect sizes are meaningful, and the human controlled trials needed to establish efficacy at the regulatory standard have not been completed.
LL-37 has a strong basic-science evidence base for its dual antimicrobial-plus-pro-healing role and is considered one of the most-studied antimicrobial peptides. Translation to clinical wound-healing therapeutics has been slowed by formulation challenges, host-response variability, and the difficulty of running adequately powered chronic-wound trials. Topical LL-37 derivatives have been explored in diabetic foot ulcer trials with mixed but encouraging signals.
What to expect
For cosmetic procedure recovery — post-laser resurfacing, post-microneedling, post-chemical peel — topical GHK-Cu applied 2-3 times daily during the recovery window typically produces reduced erythema and faster epithelialization compared with carrier-only controls. The improvement is real but incremental; it does not eliminate downtime.
For surgical incisions and traumatic skin injuries, BPC-157 used systemically (subcutaneous injection) is reported to accelerate visible wound closure and improve final scar quality in user reports. Animal data support these claims; human controlled data do not yet exist at high quality.
For chronic non-healing wounds (diabetic foot ulcers, venous stasis ulcers, pressure ulcers), peptides should be considered adjuncts to specialist wound-care management — debridement, off-loading, infection control, and underlying disease management remain the foundation. Peptides do not substitute for sharp debridement of necrotic tissue or for revascularization in critically ischemic limbs.
Important caveats
Wound healing is the area where evidence-validated standard-of-care interventions are strongest, and substituting peptides for them is dangerous. Diabetic foot ulcers in particular require multidisciplinary care; missed infection or unaddressed peripheral vascular disease can lead to amputation. Use of peptides as primary therapy for chronic wounds without specialist supervision is inappropriate. Topical peptide formulations should be sterile or appropriately preserved — applying non-sterile preparations to open wounds risks introducing infection. People on anticoagulants, with active malignancy, or with autoimmune conditions on biologic therapy should consult treating clinicians before adding peptide protocols.
Frequently asked questions
What is the best peptide for wound healing?
GHK-Cu has the deepest evidence — five decades of research, mechanistic detail, animal models, and human RCT support in post-procedure recovery. For deeper or systemic wound healing, BPC-157 has the strongest preclinical signal, particularly for soft-tissue and gastrointestinal injury. Practical use often combines a topical (GHK-Cu) with a systemic (BPC-157) on the rationale that they target different layers of the healing cascade.
Does GHK-Cu actually speed up wound healing?
Yes, the evidence is reasonable. The 2007 Abdulghani RCT in 100 patients showed reduced erythema and faster recovery after CO₂ laser resurfacing with topical GHK-Cu. Multiple animal models confirm increased collagen synthesis, faster wound closure, and improved tensile strength of healed tissue. The effect is real but modest — GHK-Cu accelerates healing rather than producing radically different outcomes.
Can peptides heal a chronic wound that won't close?
Maybe, as adjuncts. Chronic non-healing wounds (diabetic foot ulcers, venous stasis, pressure injuries) are first and foremost managed with the conventional wound-care toolkit — debridement, infection control, off-loading, compression, vascular evaluation. Peptide adjuncts including GHK-Cu and LL-37 derivatives have shown signals in clinical trials but are not first-line therapy. Anyone with a wound that has failed to close in 4-6 weeks should be in specialist wound-care management, with peptides considered only as adjunct to that care.
How long does it take peptides to heal a wound?
Acute clean cutaneous wounds re-epithelialize over 1-3 weeks with or without peptides — the peptide effect is acceleration of that timeline plus improved final scar quality, not change of order of magnitude. Reported acceleration in literature and clinical use is typically 20-40% faster recovery for post-procedure indications. For deeper or chronic wounds, peptide adjuncts are dosed for weeks to months.
Are peptides good for scar reduction?
GHK-Cu has documented effects on remodeling-phase scar quality — better collagen organization, reduced erythema, more pliable scar tissue at endpoint. AC-SDKP has anti-fibrotic activity that is mechanistically relevant. Topical use during the active scar-remodeling phase (4-12 weeks post-injury) is the most-studied window. For mature scars (over a year old), the evidence for peptide intervention is much thinner and physical modalities (laser, microneedling, silicone sheeting) carry stronger evidence.
Are peptides safe to use on open wounds?
Topical application of approved cosmetic-grade GHK-Cu after closed surgical incisions or laser-resurfaced skin is generally considered safe and is the most-validated use case. Application of any peptide directly to a fresh open wound should be done with sterile preparation and ideally under clinician guidance. Self-application of research-chemical-grade peptides to open wounds risks contamination and infection. Diabetic ulcers and ischemic wounds should never be self-managed with peptides as primary therapy.
Part of these goals
Related conditions
Peptide families relevant to Wound Healing
Copper Peptides
A family of small copper-binding tripeptides — GHK-Cu, AHK-Cu, and palmitoyl variants — that form stable copper(II) complexes with documented effects on collagen synthesis, wound healing, and skin remodeling. Founded by Loren Pickart's 1973 isolation of GHK-Cu and now a fixture of cosmetic dermatology and the wound-care literature.
Thymic Peptides
The peptide family derived from thymic tissue and its synthetic analogs — Thymosin α-1 (Zadaxin / thymalfasin, immune modulation), Thymosin β-4 (TB-500, tissue repair through actin sequestration), Thymalin (Russian-tradition thymic-extract preparation), Thymulin (zinc-dependent thymic hormone), and Thymagen (Khavinson-program synthetic thymic peptide). Two functional branches: α-family for immune function, β-family for actin-mediated tissue repair.
Antimicrobial Peptides
The peptide family of host-defense antimicrobial peptides — LL-37 (the human cathelicidin), KPV (the alpha-MSH-derived anti-inflammatory tripeptide), lactoferricin (the lactoferrin-derived antimicrobial), DS-5, plus the broader research-tier cluster including tuftsin, hepcidin, and larazotide. Antimicrobial peptides are an active drug-development area for resistant infections, mucosal immunity, and inflammatory disease, with origins traceable to Michael Zasloff's 1987 discovery of the magainins.
Stacks that overlap
- GLOW Peptide Stack (BPC-157 + TB-500 + GHK-Cu)
GLOW is a popular pre-mixed compounded peptide blend combining BPC-157 tissue repair, TB-500 cell migration, and GHK-Cu collagen remodeling in a single 70 mg vial. Also covers the two-peptide BPC-157 + GHK-Cu pairing for practitioners sourcing vials separately.
- KLOW Peptide Stack (BPC-157 + TB-500 + GHK-Cu + KPV)
KLOW is a pre-mixed four-peptide compounded blend combining BPC-157 and TB-500 systemic repair, GHK-Cu collagen remodeling, and KPV anti-inflammatory coverage in a single 80 mg vial. It extends the popular GLOW formulation with an explicit anti-inflammatory layer.
- Wolverine Peptide Stack (BPC-157 + TB-500)
The Wolverine Stack is the most popular peptide recovery combination — BPC-157 for localized tissue repair paired with TB-500 for systemic healing, cell migration, and anti-inflammatory support.
Updated 2026-05-07